An NIH SBIR application is a for-profit U.S. small business's bid for set-aside research funding, and it is won on two things at once: scientific merit and a credible path to commercial use. You need to clear eligibility, finish four registrations, pick the right institute and phase, write the research plan and the commercialization plan, and submit by one of three yearly deadlines. Most applicants treat the commercial half as paperwork. Reviewers do not. If you are a founder or a university spinout, our team can help you build that half so it reads as a business case.
TL;DR
- Only a U.S. for-profit small business with no more than 500 employees (including affiliates) can apply, and the principal investigator must be primarily employed by that company.
- Finish SAM, eRA Commons, Grants.gov and SBA registrations first. They take time, and nothing can be submitted without them.
- Standard due dates are September 5, January 5 and April 5. Weekend and federal-holiday dates move to the next business day.
- The commercialization plan is a scored part of the application. Treat it as a market, IP, financing and revenue argument, not an appendix.
- Each unfunded application can be resubmitted once, so write the first version as if it were your only one.
Table of Contents
- Who can apply: the eligibility tests
- Complete the four registrations first
- Choose the institute, the opportunity and the phase
- Prepare and submit the application
- Write the commercialization plan
- What happens after you submit
- Why we help with the commercial half
- Our perspective
- FAQ
- Sources
Who can apply: the eligibility tests
NIH accepts SBIR applications only from U.S. small business concerns. According to NIH Grants Policy Statement section 18.5.2, the company must be for-profit, have a place of business in the U.S., operate primarily in the U.S. or contribute significantly to its economy, use an eligible legal form, meet the SBIR ownership test, and have no more than 500 employees including affiliates.
Three details trip up university founders in particular:
- The PI's employment. The contact PD/PI must have primary employment with the company at the time of award and for the duration of the project. NIDDK explains that primary means 51% or more. A professor who keeps a full-time faculty appointment usually cannot be the SBIR PI.
- Who does the work. The company must perform at least 67% of the research effort in Phase I and 50% in Phase II. Payments to consultants and contractors generally cannot exceed 33% of the requested amount in Phase I or 50% in Phase II. If your plan leans on a university lab, check the split before you draft the budget.
- Where the work happens. The research must be performed entirely in the U.S. NIH may consider rare, scientifically justified foreign-site cases.
The ownership test and the university relationship are where eligibility is decided in practice. If the technology is still owned by the university, the licensing terms between the school and your company belong in the plan before you apply, not after. That is the kind of question we work through with spinouts under IP, patent strategy and licensing.
Complete the four registrations first
Per the NIH SEED guidance, you need all of these before preparing an application:
- SAM (System for Award Management), for doing business with the federal government.
- eRA Commons, for doing business with NIH.
- Grants.gov, the federal-wide portal for submitting applications.
- SBA, for participating in SBIR and STTR programs.
Start these weeks before the deadline. Each one verifies your organization, and a mismatch in legal name or address between systems is a common cause of delay. Give the person who will submit the right roles in eRA Commons early, so the authorized organizational representative is not a last-day discovery.
Choose the institute, the opportunity and the phase
NIH is not one funder. Each institute and center has its own priorities, and only participating ones can fund a given funding opportunity. NINDS advises applicants to search NIH RePORTER for similar funded projects and to send program staff a draft Specific Aims page to confirm fit. You can request an institute assignment on the PHS Assignment form, but mission alignment governs where the application lands.
Some fit rules are narrower than they look. ORIP, for example, only considers research relevant to two or more categorical institutes. A project that mostly serves one institute's interests is not appropriate there.
Phase I, Fast-Track or Direct to Phase II
Per NIH SEED, the options are:
| Route | What it is | Fits when |
|---|---|---|
| Phase I | Feasibility, technical merit and commercial potential | You need proof of concept |
| Fast-Track | Phase I and Phase II submitted and reviewed in one application | You can set clear go/no-go feasibility criteria |
| Direct to Phase II | Skips Phase I where the funding opportunity allows it | You already have significant preliminary feasibility data and no prior Phase I |
NINDS adds a caution for Fast-Track: the Phase II plan should not depend on how Phase I turns out, and the commercialization plan has to be strong. Funding limits and phase durations are set in the funding announcement and adjusted over time, so read the current parent announcement for your institute before you build a budget. The SBIR and STTR funding opportunities page lists the active parent announcements.
NIH does not fund Phase III. NINR notes that Phase III is for the company to pursue commercialization from Phase I and II results, and that NIH offers technical assistance programs to help with that transition. This is why the plan for who pays for the next step matters so much to reviewers.
Prepare and submit the application
After you find the funding opportunity, work from the NIH Application Guide and the SBIR/STTR-specific instructions. According to NIH SEED, forms are SF-424(R&R) Version I for due dates on or after January 25, 2025. You can prepare in ASSIST, which uses eRA Commons credentials, in Grants.gov Workspace, or through a system-to-system solution. NIH reports that about 75% of HHS small business applicants use ASSIST.
Two rules save you from avoidable errors. Instructions in the funding opportunity override the Application Guide, and notices in the NIH Guide for Grants & Contracts override both. There is also no option to download forms and mail them in.
Deadlines
The NIH SEED funding page gives standard due dates of September 5, January 5 and April 5, moved to the next business day when they fall on a weekend or federal holiday. Individual announcements can carry their own dates, so confirm yours there.

Submit early. Before the due date you can correct errors and resubmit through Grants.gov. After it, corrections count as late and need a cover letter explaining the delay. NIH's application guide also says that failing to follow stated policies can lead to an application being returned without review. Aim to have a clean, error-free submission several days before the due date so you have time to fix system errors.
Write the commercialization plan
This is the part of the application most scientific teams under-build, and the part we can help most with. NIH's G.440 form instructions organize the plan into six sections:
- Value of the project, expected outcomes and impact. What problem the product solves and what changes if it works.
- Company. Who you are and why this team can execute.
- Market, customer and competition. Who buys, what they use today, and why they would switch.
- Intellectual property protection. What you own or control and how it protects the product.
- Finance plan. The financing needed, when, and how you will raise it. This can include funding commitments, letters of intent, in-kind support or steps toward Phase III funding.
- Revenue stream. How the company will earn revenue and how staffing changes to meet it.
The NIDA commercialization plan guide offers a longer outline that is useful as a thinking checklist. It caps the plan at 12 pages and adds regulatory strategy, production and marketing, and risk analysis and mitigation. Even where your form has fewer headings, those topics are what a skeptical reviewer will ask about.
What each section needs to prove
- Market. Replace a single large top-down number with a defined customer segment, a count of those customers and a price assumption. Our guide to biotech market research shows how to size and validate a market.
- IP. State what is filed, what is licensed in and from whom, and where freedom to operate stands. A patent landscape analysis shows reviewers you know the field, and IP due diligence shows what an investor or partner will check.
- Regulatory. For devices, tie your milestones to a pathway. Our guides on medical device regulatory strategy and the FDA De Novo pathway cover the common routes.
- Finance. Connect the grant to the next round of capital. Our piece on matching capital to milestones is built for this. A plan that names who will fund Phase III, and what they need to see, is stronger than one that says investors will follow. Strategy that spans commercialization and contracting is also covered in the commercialization and contracting guidance that Sharon Creek Ventures publishes for energy founders.
- Revenue. Show the first revenue event, the price, the customer and the hires it requires.
The common failure is a plan that describes the technology again. Reviewers already read that in the research strategy. The plan has to describe the business around it.
What happens after you submit
Per NIAMS, three reviewers independently evaluate each application and give an initial score. The review officer ranks all applications by the average. At the meeting, reviewers discuss only the top half, and only discussed applications receive an impact score. The rest are marked Not Discussed. Every applicant, scored or not, receives reviewer critiques in a summary statement, normally within a month of the review.
If you win, plan your cash. NIH SEED webinar slides note that, for SBIR contracts, funds are not disbursed at award. Invoices follow completed activities or reports, and each institute may set its own payment schedule. The company needs enough resources to start work and carry costs between payments.

Resubmission
If the application is not funded, NIH allows one resubmission, called an A1, for each unfunded SBIR proposal. The SBIR.org resubmission guide says it must come within 37 months of the original receipt date. The cover letter and the Application Type field must both identify it as a resubmission. Use the summary statement as a punch list: answer each criticism directly and visibly, especially those that touch commercial potential.
Why we help with the commercial half
We are Tech Transfer Advisors, and our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. Our services include funding strategy covering SBIR/STTR and non-dilutive grants, market assessments, and IP and licensing support. Legal matters are coordinated with our IP law partner. For an applicant, that means the market section, the IP section and the finance plan can be written by people who have seen those sections from the reviewer's side of the table and the licensing side of the table.
We work in life sciences, medical devices and engineering. If your project is a spinout, we can also help with the formation work that has to precede the application. Details are on our services page.

If you are planning an NIH SBIR application, start with a conversation about your technology, your ownership position and your timeline. Talk to Tech Transfer Advisors about funding strategy, IP and the commercialization plan.
Our perspective
Most SBIR applications we would flag are not weak in science. They are weak in the connections: between the license and the company, between the market claim and a named customer, between the grant and the money that comes after it.
Our view is that you should settle ownership, IP and the Phase III story before you write the first page of the research strategy. Those answers shape the budget, the PI choice and the commercialization plan, and they are far harder to repair after a summary statement arrives.
We build these plans from direct experience in university tech transfer, grant review and industry commercialization, with IP counsel coordinated through our legal partner. That is how we aim to give every section a reason to exist.
the author
FAQ
How many times can you submit an NIH SBIR application?
You can submit a new application at each standard due date. After an unfunded application, NIH allows one resubmission, called an A1, within 37 months of the original receipt date. Mark it as a resubmission in both the cover letter and the Application Type field.
Where does SBIR funding come from?
It comes from a set-aside of NIH's research and development budget reserved for small businesses. NIH describes it as a program for domestic small businesses doing biomedical R&D with commercial potential. The amounts available for each phase are stated in the current funding announcement.
Can a university researcher apply for an NIH SBIR?
Not directly. The applicant must be a for-profit U.S. small business, and the PI must be primarily employed by it. A researcher usually needs a company, a license to the technology and a clear division of work with the university lab.
How long should the commercialization plan be?
NIDA's guide says up to 12 pages, with nine topic areas. NIH's G.440 instructions organize the core content into six sections. Check the funding opportunity you are using for the exact requirement.
Sources
- NIH Grants Policy Statement 18.5.2 Eligibility
- NIDDK R43/R44 SBIR
- NIH SEED: Before You Apply
- NINDS Small Business Program FAQs
- ORIP Small Business Program Selection
- NIH SEED: SBIR and STTR Funding Opportunities
- NINR Small Business Program: How to Apply
- NIH SEED: Prepare Your Application
- NIH SF424 R&R Application Guide
- NIH G.440 SBIR/STTR Information Form
- NIDA Commercialization Plan Guide
- NIAMS SBIR/STTR FAQs
- NIH SEED HHS SBIR Contract Webinar slides
- SBIR.org NIH SBIR Resubmission guide
